Show simple item record

dc.contributor.authorMulhearn, Ben
dc.contributor.authorBruce, Ian N
dc.date.accessioned2014-11-27T09:51:12Zen
dc.date.available2014-11-27T09:51:12Zen
dc.date.issued2014-11-17en
dc.identifier.citationIndications for IVIG in rheumatic diseases. 2014: Rheumatologyen
dc.identifier.issn1462-0332en
dc.identifier.pmid25406359en
dc.identifier.doi10.1093/rheumatology/keu429en
dc.identifier.urihttp://hdl.handle.net/10541/336214en
dc.description.abstractThe use of IVIG to treat a wide variety of immune-driven diseases has grown rapidly, although the mechanism of action is not completely understood. Increasing demand for IVIG coupled with concerns regarding potential transmissible agents has led to worldwide supply shortages. National agencies have therefore produced guidelines for its use, with the latest England and Wales guideline being published in 2011. Due to the rarity of the rheumatic diseases, the evidence for IVIG use has been shown to be lacking in some areas and promising in others. Conditions in which IVIG has been shown to have benefit include ITP, Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy occurring in the context of rheumatic disease, as well as in SLE, idiopathic inflammatory myopathies and ANCA-associated vasculitides. This review looks at current IVIG use and is designed to be an aid for rheumatologists when considering the use of IVIG in clinical practice.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to Rheumatology (Oxford, England)en
dc.titleIndications for IVIG in rheumatic diseases.en
dc.typeArticleen
dc.contributor.departmentChristie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalRheumatologyen
html.description.abstractThe use of IVIG to treat a wide variety of immune-driven diseases has grown rapidly, although the mechanism of action is not completely understood. Increasing demand for IVIG coupled with concerns regarding potential transmissible agents has led to worldwide supply shortages. National agencies have therefore produced guidelines for its use, with the latest England and Wales guideline being published in 2011. Due to the rarity of the rheumatic diseases, the evidence for IVIG use has been shown to be lacking in some areas and promising in others. Conditions in which IVIG has been shown to have benefit include ITP, Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy occurring in the context of rheumatic disease, as well as in SLE, idiopathic inflammatory myopathies and ANCA-associated vasculitides. This review looks at current IVIG use and is designed to be an aid for rheumatologists when considering the use of IVIG in clinical practice.


This item appears in the following Collection(s)

Show simple item record